Introduction: type 1 diabetes (t1D) is caused by the autoimmune destruction of pancreatic β cells, resulting from coincident genetic predisposition and some environmental triggers. signal transducer and activator of transcription 4 (stat4) gene encodes a transcription factor, which promotes th1 cell differentiation, interferon γ production, and development of th17 cells. Polymorphisms of stat4 are associated with several autoimmune conditions, while studies in t1d provided inconsistent results. this analysis was designed to investigate the association of stat4 rs7574865 with t1d in Polish children and to assess stat4 expression in newly diagnosed subjects. Material and methods: rs7574865 was genotyped in 656 t1d children and 782 healthy individuals. stat4 mrna expression was analyzed in peripheral blood mononuclear cells (PBMcs) from 29 children with t1d and 27 age-matched controls. β-cell and thyroid-specific serum autoantibodies were assessed with radioimmunoassays. Results: the distribution of rs7574865 genotypes and alleles demonstrated significant difference (p = 0.002, p < 0.001, respectively) between patients vs. controls. carriers of the minor t allele presented earlier t1d onset (p = 0.017). no differences were found in β-cell autoantibody in genotype-stratified patients (p > 0.050), while anti-thyroid antibodies were more frequent in carriers of the minor allele (p = 0.039 for anti-thyroperoxidase, p = 0.007 for anti-thyroglobulin antibodies, respectively). stat4 was overexpressed in PBMcs from t1d patients (p = 0.008), especially subjects with two/three circulating β-cell antibodies (p < 0.001). Conclusions: the study confirms an association of stat4 rs7574865 with t1d in Polish patients, and provides an evidence for its relationship with an earlier disease onset and concomitant thyroid autoimmunity. stat4 expression appears elevated in t1d, especially with more severe reaction against β-cell antigens.
ObjectivesCisplatin and mitomycin C exert high activity towards BRCA1-deficient cells. This study aimed to evaluate the efficacy of a combination of these drugs in hereditary BRCA1-associated ovarian cancer (OC).MethodsTwelve OC patients, who could not be treated by primary debulking surgery owing to extensive tumor spread, were given neoadjuvant cisplatin (100 mg/m2) and mitomycin C (10 mg/m2) every 4 weeks for 3 (n = 9), 2 (n = 2), or 4 (n = 1) cycles.ResultsThe decrease of tumor burden and complete surgical cytoreduction were achieved in all patients. Pathologic complete response, defined as the absence of tumor cells in surgically removed tissues, was observed in 2 (17%) of 12 cases. Retrospective analysis of 62 OC in BRCA1 mutation carriers subjected to conventional neoadjuvant chemotherapy schemes revealed 36 objective tumor responses (58%) and 37 instances (60%) of complete cytoreductive surgery; however, none of these patients demonstrated pathologic complete response.ConclusionsThe combination of cisplatin plus mitomycin C showed promising results in BRCA1-driven OC and therefore deserves further clinical evaluation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.